Holen Sie sich die Stockscreener-App
39.68
3.71%
-1.53
Schlusskurs vom Vortag:
$41.21
Offen:
$41.11
24-Stunden-Volumen:
617.38K
Relative Volume:
0.95
Marktkapitalisierung:
$1.70B
Einnahmen:
$4.85M
Nettoeinkommen (Verlust:
$-114.75M
KGV:
-12.21
EPS:
-3.25
Netto-Cashflow:
$-100.36M
1W Leistung:
-5.14%
1M Leistung:
-6.15%
6M Leistung:
+115.89%
1J Leistung:
+71.03%
1-Tages-Spanne:
$38.74
$41.52
1-Wochen-Bereich:
$38.74
$42.93
52-Wochen-Spanne:
$13.37
$45.45
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Vergleichen Sie DNTH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
39.68 | 1.77B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.3%What's Next? - MarketBeat
Dianthus Therapeutics, Inc. $DNTH Stake Lessened by Moody Aldrich Partners LLC - MarketBeat
ETF Watch: Why Dianthus Therapeutics Inc stock could outperform in 2025Market Movement Recap & AI Enhanced Execution Alerts - moha.gov.vn
Dianthus, Nanjing Leads Biolabs initiate Phase 1 trial of LBL-047 - MSN
Leads Biolabs and Dianthus Therapeutics Initiate Phase 1 Trial for LBL-047 (DNTH212), a Bifunctional Fusion Protein Targeting Autoimmune Disorders - Quiver Quantitative
Leads Biolabs And Dianthus Therapeutics Announce Initiation Of Phase 1 Trial Of LBL-047 (Dnth212) In Healthy Volunteers And Patients With Systemic Lupus Erythematosus - TradingView — Track All Markets
New lupus drug test begins, aiming for simple self-injections every month - Stock Titan
Wedbush Reiterates Outperform Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics Earnings Notes - Trefis
How big funds are accumulating Dianthus Therapeutics Inc. (87E) stockPortfolio Return Report & High Conviction Investment Ideas - Улправда
Aug Closing: How big funds are accumulating Dianthus Therapeutics Inc. (87E) stockJuly 2025 Recap & Daily Profit Focused Screening - Улправда
Wall Street Recap: Is Dianthus Therapeutics Inc. stock overvalued by current metricsCPI Data & AI Enhanced Trading Signals - Улправда
First Week of August 2026 Options Trading For Dianthus Therapeutics (DNTH) - Nasdaq
Why Dianthus Therapeutics Inc. (87E) stock fits value portfoliosQuarterly Risk Review & Daily Oversold Stock Bounce Ideas - Улправда
Bain Capital Life Sciences Investors LLC Has $46.24 Million Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. $DNTH Shares Sold by 5AM Venture Management LLC - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
What drives Dianthus Therapeutics Inc 87E stock priceLow Risk Investment Ideas & Low Cost Trading Tips - earlytimes.in
EBIT per share of Dianthus Therapeutics, Inc. – GETTEX:87E - TradingView — Track All Markets
Dianthus Therapeutics (NASDAQ:DNTH) CFO Ryan Savitz Sells 20,000 Shares - MarketBeat
Dianthus Therapeutics CFO & CBO Ryan Savitz Sells 20,000 Shares - TradingView — Track All Markets
CFO Savitz Sells 20,000 ($903.6K) Of Dianthus Therapeutics Inc [DNTH] - TradingView
Ashland, Bitdeer, and More Stocks See Action From Activist Investors - Barron's
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighHere's Why - MarketBeat
Nothing is Better Than Dianthus Therapeutics Inc (DNTH) stock at the moment - setenews.com
27,003 Shares in Dianthus Therapeutics, Inc. $DNTH Bought by XTX Topco Ltd - MarketBeat
Geode Capital Management LLC Has $9.04 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 45.0 USD By Investing.com - Investing.com Nigeria
Can Dianthus Therapeutics Inc. (87E) stock sustain breakout momentum2025 AllTime Highs & Detailed Earnings Play Alerts - Newser
CFO Savitz Files To Sell 20,000 Of Dianthus Therapeutics Inc [DNTH] - TradingView — Track All Markets
Is Dianthus Therapeutics Inc. (87E) stock a contrarian opportunityWeekly Loss Report & Real-Time Volume Analysis - Newser
Dianthus Therapeutics stock hits 52-week high at 45.0 USD - Investing.com
Can Dianthus Therapeutics Inc. (87E) stock deliver double digit returnsPortfolio Performance Report & Low Drawdown Momentum Trade Ideas - Newser
Will Dianthus Therapeutics Inc. (87E) stock outperform value peersTrade Risk Assessment & Low Risk High Reward Ideas - Newser
Dianthus Therapeutics, Inc. $DNTH Shares Bought by Sio Capital Management LLC - MarketBeat
CapEx per share of Dianthus Therapeutics, Inc. – TRADEGATE:87E - TradingView
Dianthus Therapeutics (DNTH) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
DNTH: Advancing two autoimmune therapies with strong clinical data and $525M cash runway - TradingView
Ensign Peak Advisors Inc Invests $2.50 Million in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Stocks of Dianthus Therapeutics Inc (DNTH) are poised to climb above their peers - Setenews
Fed fueled market rally dnth breakout setup and ethereums critical test zone ahead | Fundamental analysis - RichTv
Avidity Partners Management LP Reduces Stake in Dianthus Therape - GuruFocus
What analysts say about Dianthus Therapeutics Inc stockStock Buy Signals & Top Analyst Picks Available for Free - earlytimes.in
Dianthus Therapeutics stock hits 52-week high at 43.69 USD By Investing.com - Investing.com Nigeria
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):